Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rectal Neoplasms × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Rectal Neoplasms 1 Pleural Effusion 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Insulin-Like Growth Factor I, Resistance To 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Oxaliplatin 132 Fluorouracil 124 Capecitabine 106 Leucovorin 98 Irinotecan 75 Radiotherapy 63 Bevacizumab 59 Cetuximab 41 Folfox protocol 25 Surgical Procedures, Operative 22 Drug Therapy 21 Radiation 18 Panitumumab 17 XELOX 16 Chemotherapy, Adjuvant 15 Neoadjuvant Therapy 14 Chemoradiotherapy 13 Radiotherapy, Intensity-Modulated 12 Floxuridine 10 regorafenib 8 Nivolumab 8 raltitrexed 7 aflibercept 7 IFL protocol 7 Celecoxib 7 trifluridine tipiracil drug combination 6 sintilimab 6 Trastuzumab 6 Melphalan 6 Magnetic Resonance Spectroscopy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡